vantictumab (OMP-18R5) - Mereo Biopharma, Bayer
MorphoSys: Company Update (Morphosys) - Nov 26, 2015 - Anticipated data from P1 trial (NCT01957007) for NSCLC in 2015; Anticipated data from P1 trial (NCT02005315) for pancreatic cancer in 2015; Anticipated data from P1 trial (NCT01345201) for solid tumors in 2016 
Anticipated P1 data Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer
https://www.morphosys.com/sites/default/files/presentations/151123_company_update.pdf
 
Nov 26, 2015
 
.
 
166dc600-6392-41bb-aaaf-1edef15d3ef8.jpg